Medical imaging has recently advanced so rapidly that it should halt. Applying more power to computed tomography (CT) and magnetic resonance imaging (MRI) scanners is becoming too dangerous for patients and healthcare workers. Magnets for the next-generation MRIs are so powerful that they must be moved to a separate building on hospital campuses, while CT radiation levels have risen to alarming…
Although developments in molecular imaging still do not reach the high expectations placed upon them, the change in imaging is very obvious. Having been limited to the imaging of morphology, nowadays information on tissue characteristics, blood vessels or the metabolic behaviour of tumours provide many more insights, for example into response behaviour.
Breast cancer can develop very differently in different women. Researchers in Norway are improving breast cancer diagnostics and treatment by identifying the various tumour types. The objective is to find out as much as possible about the various tumour types so that each patient can receive precisely the right treatment at the right time.
Molecular imaging (MI) is reported as an increasingly important diagnostic field for radiologists to focus on. However, molecular imaging should not be considered a new discipline that only adds to today’s clinical practice, or might even replace the traditional, more morphology-oriented diagnosis. Rather, the whole diagnostic concept should be re-considered.
Molecular Imaging (MI) emerged in the early 21st Century as a discipline at the junction of molecular biology and in vivo imaging to enable the visualisation of the cellular function and the follow-up of the molecular processes in living organisms. Modalities available for MI encompass MRI, CT and ultrasound, PET, as well as Optical Imaging, and are by nature frequently experimental.
A leading radiologist is forecasting a ‘paradigm shift’ in breast imaging. Dr Peter Brader, from Department of Radiology, Division for Molecular and Gender Imaging, Medical University Vienna, envisages that diagnosis and treatment will move from a ‘one size fits all’ approach to one of personalised molecular medicine by 2025. He also foresees greater use of theranostics with combinations…
Molecular imaging (MI) appears as an unavoidable challenge for the future of imaging, because MI is able to characterise cellular and molecular processes and will serve as a guide for new targeted or personalised therapies. However, MI appears as hype for many radiologists because it is too far from clinical practice. In reality, MI is already part of clinical practice using PET and targeted…
This one-day symposium will expose the Europe and Israeli research communities to the latest advanced technologies that provide temporal and spatial information on cell fate from the living organism. This event is open to anyone interested, please feel welcome to attend! Registration is mandatory. Participation is free of charge.
"One size fits all" – the phrase is a fact of life in terms of the drugs available to treat cancer patients today. This solution can bear tragic results. Only 25% of cancer patients currently respond to this ‘one size’ drugs administration. In addition, 100,000 patients die annually, in the USA alone, from the side effects of those drugs. Personalised therapies that are devised to suit…
When planning radiotherapy the combination of positron emission tomography (PET) and Computed tomography (CT) can provide a better outcome than CT alone. Michael Krassnitzer asked Terri Bresenham MSc BSc, Vice President for Molecular Imaging at GE Healthcare, for her views on the value of PET/CT, the new EANM guidelines, novel tracers and the future of other hybrid imaging technologies.
High resolution radionuclide imaging is a technique increasingly used to detect breast cancers and has already been shown to offer improved diagnosis in many clinical situations. The technique, which will be discussed at RSNA 2010 (28 November to 3 December, Chicago) , is also allowing clinicians to detect previously unknown areas of breast cancer in women with newly-diagnosed disease.
Molecular imaging, the discipline that unites molecular biology and in vivo imaging technologies to assess biological activity in the body, promises to open up ‘…an entire new universe,’ declared Dr Ralph Weissleder, of the Centre for Molecular Imaging Research at Massachusetts General Hospital, USA, in the journal Radiology. That was just one decade ago. And he was right. It has indeed…
Siemens Healthcare was presenting its latest solutions for the early detection and treatment of breast cancer at the German Radiology Congress in Berlin. These Breast Care Solutions include a variety of imaging procedures, such as ultrasound, mammography, and magnetic resonance imaging (MRI), supplemented by IT and laboratory diagnostic solutions. Siemens places special focus on the third…
In the current economic environment the introduction of novel imaging approaches and their reimbursement by payers is becoming increasingly difficult. Historically, this denotes a significant change, in that many currently accepted routine tests or interventions were accepted based on common sense, convincing experience or rapid adoption into clinical routine without much scrutiny.
Over the past decades new imaging technologies have substantially broadened the range of imaging applications in clinical medicine. For years anatomical imaging modalities, such as X-ray and CT, reveal high-resolution information of organs and tissues over extended imaging ranges. Lately, however, the idea of functional imaging e.g. the visualisation of physiology in vivo gains importance.
While biomarkers are acknowledged as useful tools in the early assessment of patient response to treatment, radiologists are less clear on how they can be applied in clinical practice. The ECR session Biomarkers: new word, new world, new work? explored a number of new applications for biomarkers with senior radiologists discussing their relevance in different areas.
Molecular imaging, the discipline that unites molecular biology and in vivo imaging technologies to assess biological activity in the body, promises to open up ‘…an entire new universe,’ declared Dr Ralph Weissleder, of the Centre for Molecular Imaging Research at Massachusetts General Hospital, USA, in the journal Radiology. That was just one decade ago. And he was right. It has indeed…
Clinicians gathering in Brussels for the first-ever conference on Molecular Imaging in Radiation Oncology (MIRO), from 18-20 March, will take the first steps toward setting practice guidelines for using PET scans to target radiotherapy, a task that will culminate with publication of these recommendations in September.
Molecular imaging, a new science that emerged from molecular biology, is unlike traditional imaging. Whilst the latter can, for example, show the differences in proton density or water content on MRI, molecular imaging uses biomarkers (probes) that interact selectively with molecules within an area and then generate the image according to fine molecular alterations occurring inside (e.g. within a…
A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin, USA, to GE Healthcare. The method uses imaging probes with a radiopharmaceutical compound. Under the license GE will further evaluate and develop the technology and will have an option to commercialize it.
At RSNA 2009, GE Healthcare is presenting a big basket filled with trends and innovations for the radiology department:
'Personalized medicine' -- where therapy is designed for the individual patient -- is a popular concept in healthcare today, but according to a new market research report, it will be driven by the imaging industry, especially the new molecular technologies. If images can reveal not just the heightened metabolic activity characteristic of tumors but the tumors' chemical signatures, physicians can…
Chirurgen an der Charité haben in kolorektalem Tumorgewebe eine spezifische Anhäufung von Protoporphyrin-IX (PpIX), einem rot-fluoreszierenden Vorläufermolekül des Häms beobachtet. Wir konnten zeigen, dass diese Anhäufung von PpIX darauf zurückzuführen ist, dass das Enzym, das PpIX normalerweise in Häm überführt, die sogenannte…
This year's AACC, held in conjunction with the Canadian Society for Clinical Chemists, and the Annual Meeting of the American Society for Clinical Laboratory Science, featured around 200 educational sessions and drew in over 18,000 delegates and exhibitors from almost 100 countries.
Breast-specific gamma imaging (BSGI) is a promising new technology designed to supplement mammography and breast ultrasound examinations when these show suspicious findings. By helping to detect early stage breast cancer it may reduce significantly the number of negative biopsies performed. Dilon Technologies (Newport News, Virginia), pioneer of this technology, received the CE Mark to sell its…
